Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group

Blood (2016) 128 (22): 145.

https://doi.org/10.1182/blood.V128.22.145.145

Published: 2016

Journal Articles

Modeling the Epidemiology of Chronic Lymphocytic Leukemia (CLL) in France

Xavier Troussard, MD PhD, Alain Herrera, MD, Edouard Cornet, Philippe Solal-Céligny, MD

Blood (2014) 124 (21): 5652.

https://doi.org/10.1182/blood.V124.21.5652.5652

Published: 2014

Journal Articles

Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study

Blood (2014) 124 (21): 146.

https://doi.org/10.1182/blood.V124.21.146.146

Published: 2014

Journal Articles

Modeling the Epidemiology of Indolent Non-Hodgkin Lymphoma (iNHL) in France

Xavier Troussard, MD PhD, Alain Herrera, MD, Edouard Cornet, Philippe Solal-Céligny, MD

Blood (2014) 124 (21): 5371.

https://doi.org/10.1182/blood.V124.21.5371.5371

Published: 2014

Journal Articles

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Blood (2014) 124 (3): 420–425.

https://doi.org/10.1182/blood-2013-12-538975

Published: 2014

Includes: Supplemental data

Journal Articles

The Ribvd Regimen (Rituximab IV, Bendamustine IV, Velcade SC, Dexamethasone IV) Offers a High Complete Response Rate In Elderly Patients With Untreated Mantle Cell Lymphoma. Preliminary Results Of The Lysa Trial “Lymphome Du Manteau 2010 SA”

Blood (2013) 122 (21): 370.

https://doi.org/10.1182/blood.V122.21.370.370

Published: 2013

Journal Articles

Circulating t(14;18)+ Cells As Predictive Markers Of Follicular Lymphoma Development

Sandrine Roulland, Pharm.D., Ph.D., Ester Morgado, Rachel Kelly, Jocelyne Stephanie Sungalee, Philippe Colombat, MD, PhD, Philippe Solal-Celigny, MD, Gilles Andre Salles, MD, PhD, Paolo Vineis, Bertrand Nadel, PhD

Blood (2013) 122 (21): 364.

https://doi.org/10.1182/blood.V122.21.364.364

Published: 2013

Journal Articles

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Blood (2013) 121 (18): 3650–3657.

https://doi.org/10.1182/blood-2012-10-458695

Published: 2013

Includes: Supplemental data

Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Blood (2011) 118 (21): 2445.

https://doi.org/10.1182/blood.V118.21.2445.2445

Published: 2011

Journal Articles

Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)

Gilles Andre Salles, Franck Morschhauser, MD, PhD, Catherine Thieblemont, MD, Philippe Solal-Celigny, Thierry Lamy, MD, PhD, Herve Tilly, Pierre Feugier, MD, PhD, Steven Le Gouill, MD, PhD, Emmanuel Gyan, MD, PhD, Reda Bouabdallah, MD, Michael K. Wenger, MD, Elisabeth Wassner-Fritsch, Elina Asikanius, Guillaume Cartron, MD, PhD

Blood (2011) 118 (21): 268.

https://doi.org/10.1182/blood.V118.21.268.268

Published: 2011

Journal Articles

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

Franck Morschhauser, MD, PhD, Guillaume Cartron, MD, PhD, Catherine Thieblemont, MD, Philippe Solal-Celigny, Corinne Haioun, MD, Reda Bouabdallah, MD, Thierry Lamy, MD, PhD, Noel Milpied, MD, Steven Le Gouill, MD, PhD, Pierre Feugier, MD, PhD, Michael K. Wenger, Elisabeth Wassner-Fritsch, Elina Asikanius, Gilles Andre Salles

Blood (2011) 118 (21): 3655.

https://doi.org/10.1182/blood.V118.21.3655.3655

Published: 2011

Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Blood (2011) 118 (21): 3521.

https://doi.org/10.1182/blood.V118.21.3521.3521

Published: 2011

Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Blood (2010) 116 (21): 1390.

https://doi.org/10.1182/blood.V116.21.1390.1390

Published: 2010

Journal Articles

Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

Arnold S. Freedman, MD, John Kuruvilla, MD, Sarit E. Assouline, MD, Andreas Engert, MD, DaeSeog Heo, MD, Philippe Solal-Celigny, MD, Paolo Corradini, MD, Gregor Verhoef, MD, PhD, Michelle A. Fanale, MD, Jennifer Bendiske, PhD, Brett Ewald, PhD, Jyotirmoy Dey, PhD, Johan Baeck, MD, Anas Younes, MD

Blood (2010) 116 (21): 284.

https://doi.org/10.1182/blood.V116.21.284.284

Published: 2010

Journal Articles

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL

Guillaume Cartron, MD, PhD, Catherine Thieblemont, MD, PhD, Philippe Solal-Celigny, MD, Franck Morschhhauser, MD, PhD, Corinne Haioun, MD, Reda Bouabdallah, MD, Thierry Lamy, MD, PhD, Noel Milpied, MD, Steven Le Gouill, MD, Pierre Feugier, MD, PhD, Joe Birkett, PhD, Michael K. Wenger, MD, Elina Asikanius, Gilles Salles

Blood (2010) 116 (21): 2878.

https://doi.org/10.1182/blood.V116.21.2878.2878

Published: 2010

Journal Articles

Effect of FCGR2A and FCGR3A variants on CLL outcome

Blood (2010) 116 (20): 4212–4222.

https://doi.org/10.1182/blood-2010-03-272765

Published: 2010

Journal Articles

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Guy Laurent, MD, PhD, Sylvie Lafaye de Micheaux, MD, Philippe Solal-Celigny, MD, Pierre Soubeyran, MD, PhD, Vincent Delwail, Hervé Ghesquières, MD, Catherine Thieblemont, MD, Eric Jourdan, MD, PhD, Lucile Beautier, Fabien Audibert, Patrick Squiban, MD, Helene Sicard, PhD, Jean-Francois Rossi, MD, PhD

Blood (2009) 114 (22): 1649.

https://doi.org/10.1182/blood.V114.22.1649.1649

Published: 2009

Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD

Blood (2009) 114 (22): 2338.

https://doi.org/10.1182/blood.V114.22.2338.2338

Published: 2009

Journal Articles

Phase I/II Study of Escalating Doses of Idarubicin in Combination with Methotrexate, Vindesine and Prednisolone in Patients with Primary Central Nervous System Lymphoma: Results of the GOELAMS LCP99 Multicenter Trial.

Gaelle Olivier, MD, Martine Gardembas, MD, Vincent Delwail, MD, Annie Le Mevel, MD, Martine Escoffre-Barbe, MD, Annie Brion, MD, Jean Michel Boulet, MD, Philippe Solal-Celigny, MD, Pierre Ingrand, MD, Philippe Colombat, MD, PhD

Blood (2009) 114 (22): 2694.

https://doi.org/10.1182/blood.V114.22.2694.2694

Published: 2009

Journal Articles

Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([ 18 F] FDG-PET/CT) in Aggressive T-Cell Lymphomas

Xavier Cahu, Caroline Bodet-Milin, Thomas Gastinne, Hervé Maisonneuve, Nadine Morineau, Gandhi Damaj, Philippe Solal-Celigny, Philippe Moreau, Henri Jardel, Philippe Moreau, Jean-Luc Harousseau, Françoise Kraeber-Bodéré, Steven Le Gouill, MD, PhD

Blood (2008) 112 (11): 2835.

https://doi.org/10.1182/blood.V112.11.2835.2835

Published: 2008

NARROW

Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group

Modeling the Epidemiology of Chronic Lymphocytic Leukemia (CLL) in France

Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study

Modeling the Epidemiology of Indolent Non-Hodgkin Lymphoma (iNHL) in France

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

The Ribvd Regimen (Rituximab IV, Bendamustine IV, Velcade SC, Dexamethasone IV) Offers a High Complete Response Rate In Elderly Patients With Untreated Mantle Cell Lymphoma. Preliminary Results Of The Lysa Trial “Lymphome Du Manteau 2010 SA”

Circulating t(14;18)+ Cells As Predictive Markers Of Follicular Lymphoma Development

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL

Effect of FCGR2A and FCGR3A variants on CLL outcome

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

Phase I/II Study of Escalating Doses of Idarubicin in Combination with Methotrexate, Vindesine and Prednisolone in Patients with Primary Central Nervous System Lymphoma: Results of the GOELAMS LCP99 Multicenter Trial.

Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([ 18 F] FDG-PET/CT) in Aggressive T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only